Buy Like Buffett
Watchlist

Flagship explainer

How Aurinia Pharmaceuticals Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$283M · 100%Cost of revenue$32.7M · 12%Gross profit$250M · 88%Operating income$105M · 37%Income before tax$114M · 40%Income tax−$173M · −61%Net income$287M · 101%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$283M100%
  • 10-K · FY 2025Filing detailsAccession 0001600620-26-000017 · filed Feb 26, 2026
Cost of revenue$32.7M12%
  • 10-K · FY 2025Filing detailsAccession 0001600620-26-000017 · filed Feb 26, 2026
$250M88%
  • 10-K · FY 2025Filing detailsAccession 0001600620-26-000017 · filed Feb 26, 2026
$105M37%
  • 10-K · FY 2025Filing detailsAccession 0001600620-26-000017 · filed Feb 26, 2026
Income before tax$114M40%
  • 10-K · FY 2025Filing detailsAccession 0001600620-26-000017 · filed Feb 26, 2026
Income tax−$173M−61%
  • 10-K · FY 2025Filing detailsAccession 0001600620-26-000017 · filed Feb 26, 2026
$287M101%
  • 10-K · FY 2025Filing detailsAccession 0001600620-26-000017 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001600620-26-000017 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

View the full Aurinia Pharmaceuticals Inc. analysis at Buy Like Buffett

AUPH income explainer — Buy Like Buffett · Buy Like Buffett